|
|
Previous Article | Table of Contents | Next Article 
Blood, 15 December 2001, Vol. 98, No. 13, pp. 3693-3698
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Structure-function analysis of the antioxidant properties of
haptoglobin
Meira Melamed-Frank,
Orit Lache,
Benjamin I. Enav,
Tal Szafranek,
Nina S. Levy,
Rebecca M. Ricklis, and
Andrew P. Levy
From the Technion Faculty of Medicine, Technion-Israel
Institute of Technology, Bat Galim, Israel.
Haptoglobin serves as an antioxidant by virtue of its ability to
prevent hemoglobin-driven oxidative tissue damage. It was recently
demonstrated that an allelic polymorphism in the haptoglobin gene is
predictive of the risk for numerous microvascular and macrovascular diabetic complications. Because these complications are
attributed in large part to an increase in oxidative stress, a study
was conducted to determine whether the different protein products of
the 2 haptoglobin alleles differed in the antioxidant protection they
provided. A statistically significant difference was found in the
antioxidant capacity of purified haptoglobin protein produced from the
2 different alleles, consistent with the hypothesis that differences in
genetically determined antioxidant status may explain differential
susceptibility to diabetic vascular complications. These differences
may be amplified in the vessel wall because of differences in the
sieving capacity of the haptoglobin types. Therefore, an attempt was
made to identify the minimal haptoglobin sequences necessary to inhibit
oxidation by hemoglobin in vitro, and 2 independent haptoglobin
peptides that function in this fashion as efficiently as native
haptoglobin were identified. Identification of the biochemical basis
for differences among haptoglobin types may lead to the rational
development of new pharmacologic agents, such as the mini-haptoglobin
described here, to avert the development of diabetic vascular complications.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. M. Nakhoul, R. Miller-Lotan, H. Awad, R. Asleh, K. Jad, N. Nakhoul, R. Asaf, N. Abu-Saleh, and A. P. Levy
Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus
Am J Physiol Renal Physiol,
April 1, 2009;
296(4):
F830 - F838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Gladwin and E. Vichinsky
Pulmonary Complications of Sickle Cell Disease
N. Engl. J. Med.,
November 20, 2008;
359(21):
2254 - 2265.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Asleh, S. Blum, S. Kalet-Litman, J. Alshiek, R. Miller-Lotan, R. Asaf, W. Rock, M. Aviram, U. Milman, C. Shapira, et al.
Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype
Diabetes,
October 1, 2008;
57(10):
2794 - 2800.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Moreno, K. R. Purushothaman, M. Purushothaman, P. Muntner, N. S. Levy, V. Fuster, J. T. Fallon, P. A. Lento, A. Winterstern, and A. P. Levy
Haptoglobin Genotype Is a Major Determinant of the Amount of Iron in the Human Atherosclerotic Plaque
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1049 - 1051.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Papp, I. Foldi, E. Nemes, M. Udvardy, J. Harsfalvi, I. Altorjay, I. Mate, T. Dinya, C. Varvolgyi, Z. Barta, et al.
Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations
Clin. Chem.,
April 1, 2008;
54(4):
697 - 704.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Blum, U. Milman, C. Shapira, R. Miller-Lotan, L. Bennett, M. Kostenko, M. Landau, S. Keidar, Y. Levy, A. Khemlin, et al.
Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2008;
28(3):
e18 - e20.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, et al.
Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2008;
28(2):
341 - 347.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Chaichana, A. P. Levy, R. Miller-Lotan, S. Shakur, and R. J. Tamargo
Haptoglobin 2-2 Genotype Determines Chronic Vasospasm After Experimental Subarachnoid Hemorrhage
Stroke,
December 1, 2007;
38(12):
3266 - 3271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Levy, K. R. Purushothaman, N. S. Levy, M. Purushothaman, M. Strauss, R. Asleh, S. Marsh, O. Cohen, S. K. Moestrup, H. J. Moller, et al.
Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Hp 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability
Circ. Res.,
July 6, 2007;
101(1):
106 - 110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Nielsen, S. V. Petersen, C. Jacobsen, S. Thirup, J. J. Enghild, J. H. Graversen, and S. K. Moestrup
A Unique Loop Extension in the Serine Protease Domain of Haptoglobin Is Essential for CD163 Recognition of the Haptoglobin-Hemoglobin Complex
J. Biol. Chem.,
January 12, 2007;
282(2):
1072 - 1079.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Blum, R. Asaf, J. Guetta, R. Miller-Lotan, R. Asleh, R. Kremer, N. S. Levy, F. G. Berger, D. Aronson, X. Fu, et al.
Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice
J. Am. Coll. Cardiol.,
January 2, 2007;
49(1):
82 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Levy, J. E. Levy, S. Kalet-Litman, R. Miller-Lotan, N. S. Levy, R. Asaf, J. Guetta, C. Yang, K. R. Purushothaman, V. Fuster, et al.
Haptoglobin Genotype Is a Determinant of Iron, Lipid Peroxidation, and Macrophage Accumulation in the Atherosclerotic Plaque
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2007;
27(1):
134 - 140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Asleh, R. Miller-Lotan, M. Aviram, T. Hayek, M. Yulish, J. E. Levy, B. Miller, S. Blum, U. Milman, C. Shapira, et al.
Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo
Circ. Res.,
December 8, 2006;
99(12):
1419 - 1425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. R. Moreno, K-R. Purushothaman, M. Sirol, A. P. Levy, and V. Fuster
Neovascularization in Human Atherosclerosis
Circulation,
May 9, 2006;
113(18):
2245 - 2252.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T R Zaccariotto, E T Rosim, D Melo, P M D Garcia, R R Munhoz, F H Aoki, and M de Fatima Sonati
Haptoglobin polymorphism in a HIV-1 seropositive Brazilian population.
J. Clin. Pathol.,
May 1, 2006;
59(5):
550 - 553.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Weiss
Handling heme
Blood,
October 1, 2005;
106(7):
2225 - 2226.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Suleiman, D. Aronson, R. Asleh, M. R. Kapeliovich, A. Roguin, S. R. Meisel, M. Shochat, A. Sulieman, S. A. Reisner, W. Markiewicz, et al.
Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients With Diabetes and Acute Myocardial Infarction
Diabetes,
September 1, 2005;
54(9):
2802 - 2806.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Lohr, D. C. Warltier, W. M. Chilian, and D. Weihrauch
Haptoglobin expression and activity during coronary collateralization
Am J Physiol Heart Circ Physiol,
March 1, 2005;
288(3):
H1389 - H1395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Levy and A. P. Levy
ELISA for Determination of the Haptoglobin Phenotype
Clin. Chem.,
November 1, 2004;
50(11):
2148 - 2150.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mustafa, T. Vukovich, T. Prikoszovich, C. Winzer, B. Schneider, H. Esterbauer, O. Wagner, and A. Kautzky-Willer
Haptoglobin Phenotype and Gestational Diabetes
Diabetes Care,
September 1, 2004;
27(9):
2103 - 2107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Levy, P. Friedenberg, R. Lotan, P. Ouyang, M. Tripputi, L. Higginson, F. R. Cobb, J.-C. Tardif, V. Bittner, and B. V. Howard
The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women
Diabetes Care,
April 1, 2004;
27(4):
925 - 930.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Fain, S. W. Bahouth, and A. K. Madan
Haptoglobin release by human adipose tissue in primary culture
J. Lipid Res.,
March 1, 2004;
45(3):
536 - 542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Philippidis, J.C. Mason, B.J. Evans, I. Nadra, K.M. Taylor, D.O. Haskard, and R.C. Landis
Hemoglobin Scavenger Receptor CD163 Mediates Interleukin-10 Release and Heme Oxygenase-1 Synthesis: Antiinflammatory Monocyte-Macrophage Responses In Vitro, in Resolving Skin Blisters In Vivo, and After Cardiopulmonary Bypass Surgery
Circ. Res.,
January 9, 2004;
94(1):
119 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Roguin, W. Koch, A. Kastrati, D. Aronson, A. Schomig, and A. P. Levy
Haptoglobin Genotype Is Predictive of Major Adverse Cardiac Events in the 1-Year Period After Percutaneous Transluminal Coronary Angioplasty in Individuals With Diabetes
Diabetes Care,
September 1, 2003;
26(9):
2628 - 2631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Asleh, S. Marsh, M. Shilkrut, O. Binah, J. Guetta, F. Lejbkowicz, B. Enav, N. Shehadeh, Y. Kanter, O. Lache, et al.
Genetically Determined Heterogeneity in Hemoglobin Scavenging and Susceptibility to Diabetic Cardiovascular Disease
Circ. Res.,
June 13, 2003;
92(11):
1193 - 1200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Levy, I. Hochberg, K. Jablonski, H. E. Resnick, E. T. Lee, L. Best, and B. V. Howard
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study
J. Am. Coll. Cardiol.,
December 4, 2002;
40(11):
1984 - 1990.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|